Net Cash Provided by (Used in) Financing Activities of Cerevel Therapeutics Holdings, Inc. from 31 Dec 2019 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2019 to 31 Mar 2024.
  • Cerevel Therapeutics Holdings, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2024 was $4,475,000, a 212% increase year-over-year.
  • Cerevel Therapeutics Holdings, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $548,616,000, a 12% decline from 2022.
  • Cerevel Therapeutics Holdings, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $623,191,000, a 47% increase from 2021.
  • Cerevel Therapeutics Holdings, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $423,602,000, a 3.9% decline from 2020.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Cerevel Therapeutics Holdings, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $4,475,000 +$3,040,000 +212% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q1 2023 $1,435,000 -$1,168,000 -45% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q1 2022 $2,603,000 +$1,861,000 +251% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q1 2021 $742,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q2 2020 $151,209,257 20 Feb 2020 30 Jun 2020 10-Q 14 Aug 2020 2020 Q2

Cerevel Therapeutics Holdings, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $548,616,000 -$74,575,000 -12% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2024 2023 FY
2022 $623,191,000 +$199,589,000 +47% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
2021 $423,602,000 -$17,233,000 -3.9% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $440,835,000 +$380,777,000 +634% 01 Jan 2020 31 Dec 2020 10-K 22 Feb 2023 2022 FY
2019 $60,058,000 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.